4,4'-Bis(2-Bromoacetyl)biphenyl CAS 4072-67-7 Daclatasvir Dihydrochloride Tsarkake Tsarkake>98.0% (HPLC)
Shanghai Ruifu Chemical Co., Ltd. shine babban kamfani na 4,4'-Bis (2-Bromoacetyl) biphenyl (CAS: 4072-67-7) tare da babban inganci.Ruifu Chemical na iya samar da isar da saƙo na duniya, farashi mai gasa, kyakkyawan sabis, ƙanana da adadi mai yawa akwai.Sayi 4,4'-Bis(2-Bromoacetyl)biphenyl,Please contact: alvin@ruifuchem.com
| Sunan Sinadari | 4,4'-Bis (2-Bromoacetyl) biphenyl |
| Makamantu | 4,4'-Bis (Bromoacetyl) biphenyl;1,1'-[1,1'-Biphenyl] -4,4'-diylbis[2-Bromoethan-1-daya];Daclatasvir rashin tsarki 7 |
| Matsayin Hannun jari | A Stock, Kasuwancin Kasuwanci |
| Lambar CAS | 4072-67-7 |
| Tsarin kwayoyin halitta | Saukewa: C16H12Br2O2 |
| Nauyin Kwayoyin Halitta | 396.07 g/mol |
| Matsayin narkewa | 226.0 ~ 227.0 ℃ |
| Yawan yawa | 1.622± 0.06 g/cm3 |
| COA & MSDS | Akwai |
| Asalin | Shanghai, China |
| Kashi | Matsakaicin Daclatasvir Dihydrochloride (CAS: 1009119-65-6) |
| Alamar | Ruifu Chemical |
| Abubuwa | Ƙayyadaddun bayanai | Sakamako |
| Bayyanar | M | M |
| Tsarkake / Hanyar Bincike | 98.0% (HPLC) | 98.5% |
| Infrared Spectrum | Daidai da Tsarin | Ya bi |
| 1H NMR Spectrum | Daidai da Tsarin | Ya bi |
| Kammalawa | An gwada samfurin kuma ya dace da ƙayyadaddun da aka bayar | |
| Aikace-aikace | Matsakaicin Daclatasvir Dihydrochloride (CAS: 1009119-65-6) | |
Kunshin:Fluorinated Bottle, Aluminum tsare jakar, 25kg / Kwali Drum, ko bisa ga abokin ciniki ta bukata.
Yanayin Ajiya:Ajiye akwati sosai kuma a adana a cikin sanyi, busasshe kuma mai cike da iska daga abubuwan da ba su dace ba.Kare daga haske da danshi.
Jirgin ruwa:Isar da shi zuwa duniya ta iska, ta FedEx / DHL Express.Bayar da isarwa cikin sauri kuma abin dogaro.
Yadda ake siya?Da fatan za a tuntuɓiDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
Kwarewar Shekaru 15?Muna da fiye da shekaru 15 na gwaninta a cikin ƙira da fitarwa na matsakaicin matsakaicin magunguna masu inganci ko sinadarai masu kyau.
Manyan Kasuwanni?Sayarwa zuwa kasuwannin cikin gida, Arewacin Amurka, Turai, Indiya, Koriya, Jafananci, Australia, da sauransu.
Fa'idodi?Babban inganci, farashi mai araha, sabis na ƙwararru da tallafin fasaha, bayarwa da sauri.
inganciTabbaci?Tsananin kula da ingancin inganci.Kayan aikin ƙwararru don bincike sun haɗa da NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Clarity, Solubility, gwajin ƙayyadaddun ƙwayoyin cuta, da sauransu.
Misali?Yawancin samfurori suna ba da samfurori kyauta don ƙima mai kyau, farashin jigilar kaya ya kamata a biya ta abokan ciniki.
Binciken Masana'antu?Ma'aikata duba maraba.Da fatan za a yi alƙawari a gaba.
MOQ?Babu MOQ.Karamin tsari abin karɓa ne.
Lokacin Bayarwa? Idan cikin hannun jari, garantin isar da kwana uku.
Sufuri?By Express (FedEx, DHL), ta Air, ta Teku.
Takardu?Bayan sabis na tallace-tallace: COA, MOA, ROS, MSDS, da dai sauransu za a iya ba da su.
Tsarin al'ada?Zai iya ba da sabis na haɗawa na al'ada don dacewa da buƙatun bincikenku.
Sharuɗɗan Biyan kuɗi?Za a fara aiko da daftari na Proforma bayan tabbatar da oda, an rufe bayanan bankin mu.Biya ta T/T (Telex Transfer), PayPal, Western Union, da dai sauransu.
4,4'-Bis (2-Bromoacetyl) biphenyl (CAS: 4072-67-7) shine matsakaici na Daclatasvir Dihydrochloride (CAS: 1009119-65-6).
Daclatasvir Dihydrochloride (Daklinza) shine mai hana cutar hanta ta C (HCV) NS5A wanda ke da amfani a cikin maganin genotype 3 na ciwon hanta na kullum.
Ranar 24 ga Yuli, 2015, FDA ta amince da maganin ciwon hanta na C na kullum (Bristol-Myers Squibb) don tallace-tallace.
Tsarin amincewa da FDA na Daklinza (Bristol-Myers Squibb) ya yi jujjuyawar juzu'i.FDA ta taɓa ƙi shi sau ɗaya, amma a ƙarshe an amince da shi a tsakiyar 2015.FDA ta amince da hadewar Daklinza da Sofosbuvir don maganin ciwon hanta na nau'in nau'in nau'in nau'in 3 na cutar hanta.
A zahiri, tun kafin amincewar FDA, an amince Daklinza don tallata a Japan, Tarayyar Turai da Koriya ta Kudu da sauran ƙasashe.A cikin 2014, sashen kiwon lafiya na Japan ya amince da aikace-aikacen Daklinza da Asunaprevir (Sunvepra) don maganin cututtukan genotype 1.Ƙungiyar Tarayyar Turai ta kuma amince da Daclatasvir da za a yi amfani da shi tare da wasu magunguna a cikin maganin HCV genotypes 1, 2, 3 da 4 a cikin 2014. Daclatasvir shine farkon NS5A hadaddun inhibitor da Tarayyar Turai (EU) ta amince da shi.Idan aka yi amfani da shi tare da wasu magunguna, idan aka kwatanta da haɗin maganin interferon da ribavirin wanda ke ɗaukar makonni 48, yana da ɗan gajeren lokacin jiyya (makonni 12 ko 24).
Daclathavir monotherapy ba a ba da shawarar ba, ƙa'idodin ƙa'idar yau da kullun ita ce haɗin gwiwa na Dacastavir + Sofosbuvir, wanda ke da alaƙa da inganci mai kyau, mafi girman SVR, ƙananan sakamako masu illa da ƙarin gajeriyar sake zagayowar jiyya fiye da sauran zaɓuɓɓuka.
